Field Medical has announced that its FieldForce ablation system was recently featured in a scientific presentation at the 2025 Heart Rhythm Society (HRS) annual meeting (24–27 April, San Diego, USA).
A late-breaking presentation of the VCAS trial on 27 April showcased acute results from first-in-human evaluations of Field Medical’s high-voltage, focal pulsed field ablation (PFA) system for the treatment of scar-related ventricular tachycardia (VT)—a novel approach targeting a “notoriously difficult” arrhythmia marked by dense fibrotic substrates and high recurrence rates.
Results from VCAS—an international, multicentre trial designed to assess the safety and performance of the FieldForce ablation system in treating scar-related VT—pertained to patients with implantable cardioverter-defibrillators (ICDs) across two centres, and revealed a fast transpired ablation time of only 35 minutes and a fluoroscopy time of 15 minutes. Additionally, in a subset of patients, the investigators demonstrated that ablation from within the heart created full-thickness ablation lesions, also translating to a 78% rate of freedom from VT. And, in this “very sick” population, two out of 22 patients experienced a significant worsening of heart failure.
“Although we’ve made significant progress in understanding scar-related VT, there remain a lack of data on the effectiveness of PFA as a treatment option—especially considering the thick, fibrotic scar tissue,” said Vivek Reddy (Mount Sinai Health System, New York, USA). “The results from the VCAS study highlight that PFA shows great promise as a treatment for scar-related VT, and the potential for this technology to transform care for complex ventricular arrhythmias is profound, likely surpassing the current standard of care.”
In a recent press release, Field Medical notes that its FieldForce ablation catheter has been engineered to reach the epicardium from the endocardium, and is designed to enable focal PFA for full-thickness, transmural lesions.
“For decades, VT has challenged even the most skilled electrophysiologists due to the complexity of the scar substrate,” said Steven Mickelsen, chief executive officer (CEO) and founder of Field Medical. “With FieldForce, we’re not just iterating—we’re redefining what’s possible. This new focal PFA system has the potential to bring PFA to the areas of greatest unmet need in electrophysiology, and the momentum we’re seeing at HRS 2025 reflects that.”
